 Gregory Forlenza
Concepts (225)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Insulin Infusion Systems | 68 | 2024 | 296 | 14.720 |
Why?
| | Diabetes Mellitus, Type 1 | 91 | 2024 | 3256 | 11.920 |
Why?
| | Blood Glucose Self-Monitoring | 65 | 2024 | 500 | 9.310 |
Why?
| | Pancreas, Artificial | 26 | 2022 | 68 | 9.210 |
Why?
| | Blood Glucose | 83 | 2024 | 1824 | 8.330 |
Why?
| | Insulin | 70 | 2024 | 2082 | 6.870 |
Why?
| | Hypoglycemic Agents | 66 | 2024 | 1008 | 6.570 |
Why?
| | Hypoglycemia | 30 | 2024 | 386 | 6.110 |
Why?
| | Hyperglycemia | 15 | 2023 | 295 | 3.620 |
Why?
| | Hematopoietic Stem Cell Transplantation | 5 | 2022 | 519 | 2.320 |
Why?
| | Monitoring, Ambulatory | 5 | 2018 | 82 | 1.800 |
Why?
| | Islets of Langerhans Transplantation | 4 | 2017 | 63 | 1.620 |
Why?
| | Diabetes Mellitus | 7 | 2022 | 908 | 1.580 |
Why?
| | Insulin-Secreting Cells | 3 | 2023 | 318 | 1.480 |
Why?
| | Pancreatectomy | 4 | 2017 | 169 | 1.480 |
Why?
| | Adolescent | 53 | 2024 | 17922 | 1.450 |
Why?
| | Child | 53 | 2024 | 18503 | 1.440 |
Why?
| | Humans | 117 | 2024 | 115741 | 1.310 |
Why?
| | Biomedical Technology | 2 | 2019 | 41 | 1.240 |
Why?
| | Patient Education as Topic | 3 | 2021 | 686 | 1.110 |
Why?
| | Verapamil | 2 | 2023 | 32 | 1.110 |
Why?
| | Pancreatitis, Chronic | 3 | 2017 | 40 | 1.100 |
Why?
| | Young Adult | 31 | 2023 | 10518 | 1.090 |
Why?
| | Telemedicine | 3 | 2022 | 667 | 0.940 |
Why?
| | Technology | 5 | 2023 | 80 | 0.890 |
Why?
| | Calcium Channel Blockers | 1 | 2023 | 115 | 0.850 |
Why?
| | Algorithms | 14 | 2020 | 1500 | 0.840 |
Why?
| | Adult | 42 | 2024 | 30789 | 0.830 |
Why?
| | Male | 48 | 2024 | 56050 | 0.810 |
Why?
| | Lymphoma | 1 | 2023 | 178 | 0.790 |
Why?
| | Female | 45 | 2024 | 60018 | 0.720 |
Why?
| | Child, Preschool | 15 | 2024 | 9138 | 0.700 |
Why?
| | Patient Dropouts | 1 | 2020 | 65 | 0.670 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 269 | 0.670 |
Why?
| | Diabetes Mellitus, Type 2 | 6 | 2023 | 2098 | 0.650 |
Why?
| | Personal Satisfaction | 1 | 2020 | 185 | 0.640 |
Why?
| | Patient Satisfaction | 2 | 2021 | 585 | 0.620 |
Why?
| | Transplantation Conditioning | 1 | 2019 | 150 | 0.600 |
Why?
| | Artificial Intelligence | 1 | 2019 | 148 | 0.590 |
Why?
| | Glucose | 8 | 2023 | 904 | 0.590 |
Why?
| | Eczema | 1 | 2018 | 82 | 0.580 |
Why?
| | Self-Management | 1 | 2019 | 126 | 0.570 |
Why?
| | Diabetic Retinopathy | 2 | 2024 | 149 | 0.570 |
Why?
| | Betacoronavirus | 1 | 2020 | 254 | 0.560 |
Why?
| | Treatment Outcome | 15 | 2024 | 9162 | 0.560 |
Why?
| | Machine Learning | 1 | 2020 | 321 | 0.560 |
Why?
| | Diffusion of Innovation | 1 | 2017 | 95 | 0.540 |
Why?
| | Insulin, Regular, Human | 7 | 2023 | 33 | 0.510 |
Why?
| | Endocrine Glands | 1 | 2015 | 16 | 0.500 |
Why?
| | Endocrine System Diseases | 1 | 2015 | 32 | 0.490 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 344 | 0.490 |
Why?
| | Coronavirus Infections | 1 | 2020 | 336 | 0.490 |
Why?
| | Fanconi Anemia | 1 | 2013 | 11 | 0.460 |
Why?
| | Dwarfism | 1 | 2013 | 15 | 0.460 |
Why?
| | Suicide | 1 | 2020 | 501 | 0.460 |
Why?
| | Skin | 1 | 2018 | 662 | 0.450 |
Why?
| | Growth Hormone | 1 | 2013 | 99 | 0.440 |
Why?
| | Diabetic Ketoacidosis | 4 | 2023 | 160 | 0.440 |
Why?
| | Quality of Life | 2 | 2020 | 2388 | 0.420 |
Why?
| | Blindness | 1 | 2012 | 37 | 0.420 |
Why?
| | Sequence Analysis, DNA | 1 | 2015 | 732 | 0.410 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2015 | 443 | 0.400 |
Why?
| | Pandemics | 1 | 2020 | 1335 | 0.390 |
Why?
| | Aged | 17 | 2022 | 19294 | 0.390 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2016 | 1218 | 0.380 |
Why?
| | Cardiovascular Diseases | 1 | 2022 | 1729 | 0.380 |
Why?
| | Angiogenesis Inhibitors | 1 | 2012 | 216 | 0.370 |
Why?
| | Retrospective Studies | 9 | 2024 | 12633 | 0.370 |
Why?
| | Cross-Over Studies | 5 | 2019 | 435 | 0.370 |
Why?
| | Calibration | 3 | 2020 | 129 | 0.370 |
Why?
| | Lingual Frenum | 1 | 2010 | 1 | 0.360 |
Why?
| | Tongue Diseases | 1 | 2010 | 8 | 0.360 |
Why?
| | Epidemics | 1 | 2011 | 70 | 0.360 |
Why?
| | Failure to Thrive | 1 | 2010 | 32 | 0.350 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2012 | 503 | 0.350 |
Why?
| | Medicaid | 3 | 2022 | 411 | 0.350 |
Why?
| | Infant | 6 | 2023 | 7979 | 0.340 |
Why?
| | Double-Blind Method | 4 | 2023 | 1660 | 0.340 |
Why?
| | Models, Biological | 1 | 2016 | 1646 | 0.340 |
Why?
| | Middle Aged | 18 | 2022 | 27069 | 0.320 |
Why?
| | Follow-Up Studies | 5 | 2021 | 4442 | 0.310 |
Why?
| | Skiing | 2 | 2019 | 40 | 0.300 |
Why?
| | Exercise | 7 | 2019 | 1609 | 0.300 |
Why?
| | United States | 11 | 2023 | 12304 | 0.290 |
Why?
| | Adolescent Nutritional Physiological Phenomena | 2 | 2017 | 25 | 0.290 |
Why?
| | Inventions | 2 | 2018 | 17 | 0.290 |
Why?
| | Transplantation, Autologous | 3 | 2017 | 173 | 0.290 |
Why?
| | Postoperative Complications | 2 | 2015 | 2164 | 0.280 |
Why?
| | Overweight | 2 | 2023 | 469 | 0.270 |
Why?
| | Risk Factors | 5 | 2020 | 8702 | 0.270 |
Why?
| | Outpatients | 2 | 2021 | 330 | 0.260 |
Why?
| | Endocrinology | 2 | 2018 | 69 | 0.260 |
Why?
| | Insulin Lispro | 2 | 2022 | 35 | 0.260 |
Why?
| | Insulin Aspart | 2 | 2022 | 26 | 0.260 |
Why?
| | C-Peptide | 2 | 2023 | 138 | 0.260 |
Why?
| | Injections, Subcutaneous | 3 | 2020 | 137 | 0.250 |
Why?
| | Mutation | 1 | 2015 | 3364 | 0.240 |
Why?
| | Body Height | 2 | 2017 | 180 | 0.240 |
Why?
| | Feasibility Studies | 5 | 2018 | 748 | 0.240 |
Why?
| | Insulins | 1 | 2023 | 32 | 0.210 |
Why?
| | Equipment Failure | 3 | 2018 | 109 | 0.210 |
Why?
| | Awareness | 1 | 2023 | 92 | 0.210 |
Why?
| | Eligibility Determination | 1 | 2022 | 60 | 0.210 |
Why?
| | Meals | 3 | 2019 | 102 | 0.200 |
Why?
| | Pediatrics | 2 | 2020 | 986 | 0.200 |
Why?
| | Automobile Driving | 1 | 2023 | 129 | 0.190 |
Why?
| | Infusion Pumps, Implantable | 1 | 2020 | 20 | 0.180 |
Why?
| | Smartphone | 2 | 2019 | 70 | 0.180 |
Why?
| | Medicare | 2 | 2022 | 668 | 0.180 |
Why?
| | Computer Systems | 1 | 2020 | 46 | 0.170 |
Why?
| | Sports | 2 | 2019 | 175 | 0.170 |
Why?
| | Prospective Studies | 5 | 2023 | 6276 | 0.170 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2019 | 63 | 0.170 |
Why?
| | Prevalence | 3 | 2023 | 2269 | 0.170 |
Why?
| | Fatal Outcome | 1 | 2020 | 286 | 0.160 |
Why?
| | Reproducibility of Results | 4 | 2024 | 2824 | 0.160 |
Why?
| | Software | 2 | 2021 | 541 | 0.160 |
Why?
| | Biosensing Techniques | 1 | 2020 | 102 | 0.160 |
Why?
| | Clinical Alarms | 1 | 2017 | 10 | 0.150 |
Why?
| | Night Terrors | 1 | 2017 | 1 | 0.150 |
Why?
| | Insulinoma | 1 | 2017 | 29 | 0.150 |
Why?
| | Obesity | 3 | 2023 | 2518 | 0.150 |
Why?
| | Device Approval | 1 | 2017 | 21 | 0.140 |
Why?
| | Diet, Diabetic | 1 | 2017 | 33 | 0.140 |
Why?
| | Survival Analysis | 1 | 2020 | 1219 | 0.140 |
Why?
| | Voluntary Health Agencies | 1 | 2016 | 5 | 0.140 |
Why?
| | Adrenal Hyperplasia, Congenital | 1 | 2017 | 28 | 0.140 |
Why?
| | Program Evaluation | 1 | 2021 | 836 | 0.140 |
Why?
| | Health Services Accessibility | 1 | 2022 | 773 | 0.140 |
Why?
| | United States Food and Drug Administration | 1 | 2017 | 173 | 0.130 |
Why?
| | Pancreaticoduodenectomy | 1 | 2017 | 130 | 0.130 |
Why?
| | Abdominal Pain | 1 | 2017 | 135 | 0.130 |
Why?
| | Age Factors | 3 | 2018 | 2911 | 0.130 |
Why?
| | Statistics as Topic | 1 | 2016 | 299 | 0.130 |
Why?
| | Drug Overdose | 1 | 2020 | 296 | 0.130 |
Why?
| | Drug Delivery Systems | 1 | 2018 | 301 | 0.130 |
Why?
| | Hypophosphatasia | 1 | 2015 | 2 | 0.130 |
Why?
| | Pilot Projects | 2 | 2020 | 1384 | 0.130 |
Why?
| | Consensus | 3 | 2023 | 537 | 0.120 |
Why?
| | Alkaline Phosphatase | 1 | 2015 | 144 | 0.120 |
Why?
| | Autografts | 1 | 2014 | 41 | 0.120 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 273 | 0.120 |
Why?
| | Glucose Clamp Technique | 1 | 2014 | 181 | 0.110 |
Why?
| | Choristoma | 1 | 2013 | 23 | 0.110 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2013 | 30 | 0.110 |
Why?
| | Quality Improvement | 1 | 2021 | 958 | 0.110 |
Why?
| | Infusions, Intravenous | 1 | 2014 | 374 | 0.110 |
Why?
| | Postoperative Period | 1 | 2014 | 293 | 0.110 |
Why?
| | Graft Survival | 1 | 2015 | 480 | 0.110 |
Why?
| | Allografts | 1 | 2013 | 127 | 0.110 |
Why?
| | Patient Compliance | 1 | 2017 | 524 | 0.110 |
Why?
| | Pituitary Gland | 1 | 2013 | 152 | 0.110 |
Why?
| | Clinical Protocols | 1 | 2014 | 233 | 0.110 |
Why?
| | Body Mass Index | 2 | 2017 | 1971 | 0.110 |
Why?
| | Bionics | 2 | 2022 | 11 | 0.110 |
Why?
| | Genetic Testing | 1 | 2015 | 382 | 0.100 |
Why?
| | Pituitary Neoplasms | 1 | 2013 | 157 | 0.100 |
Why?
| | Adipose Tissue | 1 | 2016 | 555 | 0.100 |
Why?
| | Graft Rejection | 1 | 2015 | 533 | 0.100 |
Why?
| | Adolescent Behavior | 1 | 2017 | 480 | 0.100 |
Why?
| | Prognosis | 2 | 2020 | 3343 | 0.100 |
Why?
| | Age of Onset | 1 | 2012 | 450 | 0.090 |
Why?
| | Critical Illness | 1 | 2016 | 645 | 0.090 |
Why?
| | Biomedical Research | 1 | 2016 | 589 | 0.090 |
Why?
| | Global Health | 1 | 2012 | 290 | 0.090 |
Why?
| | Pancreatic Neoplasms | 1 | 2017 | 722 | 0.090 |
Why?
| | Activities of Daily Living | 3 | 2017 | 353 | 0.090 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 4669 | 0.090 |
Why?
| | Electronic Health Records | 1 | 2016 | 805 | 0.090 |
Why?
| | Biomarkers | 1 | 2020 | 3471 | 0.090 |
Why?
| | Case-Control Studies | 1 | 2015 | 3037 | 0.080 |
Why?
| | Guideline Adherence | 1 | 2012 | 497 | 0.080 |
Why?
| | Infant, Newborn | 1 | 2019 | 5061 | 0.080 |
Why?
| | Cold Temperature | 2 | 2019 | 128 | 0.070 |
Why?
| | Equipment Design | 2 | 2019 | 517 | 0.070 |
Why?
| | Weight Gain | 1 | 2010 | 453 | 0.070 |
Why?
| | Breast Feeding | 1 | 2010 | 370 | 0.070 |
Why?
| | Incidence | 1 | 2012 | 2335 | 0.070 |
Why?
| | Seasons | 2 | 2019 | 449 | 0.070 |
Why?
| | Mass Screening | 1 | 2012 | 1024 | 0.060 |
Why?
| | Child Abuse | 1 | 2010 | 455 | 0.060 |
Why?
| | Practice Guidelines as Topic | 1 | 2012 | 1405 | 0.060 |
Why?
| | Risk | 2 | 2017 | 819 | 0.060 |
Why?
| | Diet | 1 | 2011 | 1074 | 0.060 |
Why?
| | Longitudinal Studies | 2 | 2024 | 2420 | 0.060 |
Why?
| | Combined Modality Therapy | 2 | 2017 | 1127 | 0.060 |
Why?
| | Insulin Resistance | 1 | 2011 | 1078 | 0.050 |
Why?
| | Quality-Adjusted Life Years | 1 | 2023 | 103 | 0.050 |
Why?
| | Standard of Care | 1 | 2023 | 63 | 0.050 |
Why?
| | Hospitalization | 2 | 2024 | 1765 | 0.050 |
Why?
| | Reference Standards | 1 | 2021 | 161 | 0.050 |
Why?
| | Insurance Coverage | 1 | 2022 | 204 | 0.050 |
Why?
| | Cost-Benefit Analysis | 1 | 2023 | 548 | 0.040 |
Why?
| | Intention to Treat Analysis | 1 | 2020 | 69 | 0.040 |
Why?
| | Pancreas | 1 | 2022 | 280 | 0.040 |
Why?
| | Inpatients | 1 | 2024 | 380 | 0.040 |
Why?
| | Social Conditions | 1 | 2019 | 12 | 0.040 |
Why?
| | Disease Management | 1 | 2023 | 563 | 0.040 |
Why?
| | Equipment and Supplies | 1 | 2018 | 38 | 0.040 |
Why?
| | Time Factors | 2 | 2018 | 6171 | 0.040 |
Why?
| | Postprandial Period | 1 | 2018 | 88 | 0.040 |
Why?
| | International Cooperation | 1 | 2018 | 174 | 0.040 |
Why?
| | Mobile Applications | 1 | 2020 | 140 | 0.040 |
Why?
| | Virginia | 1 | 2017 | 51 | 0.040 |
Why?
| | Colorado | 2 | 2017 | 4116 | 0.040 |
Why?
| | Snacks | 1 | 2017 | 17 | 0.040 |
Why?
| | Healthcare Disparities | 1 | 2022 | 486 | 0.040 |
Why?
| | Reference Values | 1 | 2018 | 750 | 0.040 |
Why?
| | Accelerometry | 1 | 2017 | 72 | 0.040 |
Why?
| | Ohio | 1 | 2017 | 136 | 0.040 |
Why?
| | Minnesota | 1 | 2017 | 134 | 0.030 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2017 | 97 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2017 | 255 | 0.030 |
Why?
| | Hypertrophy | 1 | 2016 | 110 | 0.030 |
Why?
| | Food Preferences | 1 | 2017 | 108 | 0.030 |
Why?
| | Materials Testing | 1 | 2017 | 356 | 0.030 |
Why?
| | Child Behavior | 1 | 2017 | 218 | 0.030 |
Why?
| | Pain Measurement | 1 | 2017 | 449 | 0.030 |
Why?
| | Societies, Medical | 1 | 2018 | 684 | 0.030 |
Why?
| | Feeding Behavior | 1 | 2018 | 573 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2022 | 6423 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1180 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2017 | 2586 | 0.020 |
Why?
| | Cohort Studies | 1 | 2017 | 4949 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2017 | 3122 | 0.020 |
Why?
|
|
Forlenza's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|